Acorn Bioventures has led a series B round for the cancer-focused biopharmaceutical spinout of CU Boulder.

OnKure, a US-based oncology therapeutics spinout of University of Colorado Boulder, secured $55m in a series B round today led by Acorn Bioventures.
Cormorant Asset Management, Surveyor Capital, Samsara BioCapital, Perceptive Advisors and funds and accounts managed by BlackRock also took part in the round.
Founded in 2011, OnKure is working on small molecule drugs that delay resistance to other targeted cancer therapies and exploit synthetic lethalities. Its lead asset, OKI-179, is now set to enter phase 2 trials and the funding will also accelerate pipeline development.
Isaac Manke, partner at Acorn, and Andrew Phillips, managing director at Cormorant, will join OnKure’s board of directors.
Delian Capital led a $7m series A round for OnKure in May 2018, when unnamed new and existing backers, including OnKure management, also took part.
The spinout previously raised $3.2m in series A-1 financing in April 2020, according to a regulatory filing, following $600,000 in June 2013 and $500,000 two months earlier, according to securities documents.

Thierry Heles

Thierry Heles is the former editor-at-large of Global University Venturing and Global Corporate Venturing, and was the producer and host of the Beyond the Breakthrough podcast until December 2024.